{
  "nctrialId": "HC-1361",
  "title": "A Randomized Double-Blind, Active-Controlled  Study of ALZ-309 (beta-amyloid antibody) in Patients With Major Depressive Disorder",
  "officialTitle": "A Randomized Double-Blind, Active-Controlled  Study of ALZ-309 (beta-amyloid antibody) in Patients With Major Depressive Disorder",
  "sponsor": "McMaster University",
  "indication": "Major Depressive Disorder",
  "phase": "Phase 1",
  "fileName": "HC-1361.json",
  "fileSize": 336536,
  "date": "2024-12-25",
  "completionDate": "2027-05-29",
  "drugName": "ALZ-309 (beta-amyloid antibody)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a randomized double-blind, active-controlled  study designed to evaluate the efficacy and safety of ALZ-309 (beta-amyloid antibody) in patients with Major Depressive Disorder. The study will enroll approximately 86 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 24-77 years\n- Confirmed diagnosis of Major Depressive Disorder\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}